Cargando…

High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy

BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Immunotherapy targeting the programmed death protein 1(PD-1) and its ligand (PD-L1), is a promising treatment option for many cancers, but has exhibited poor therapeutic efficacy in CRC. This study aimed to identif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Yuying, Zheng, Mingming, Wang, Xiaoxuan, Yu, Chenyue, Qin, Tiantian, Shen, Xuning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638725/ https://www.ncbi.nlm.nih.gov/pubmed/37950153 http://dx.doi.org/10.1186/s12885-023-11603-w

Ejemplares similares

MTNR1B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan
por: Lee, Chia-Cheng, et al.
Publicado: (2021)

Presence of PD-1 similarity genes in monocytes may promote the development of type 1 diabetes mellitus and poor prognosis of pancreatic cancer
por: Huang, Yuquan, et al.
Publicado: (2023)

CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma in vitro
por: Dai, Wei, et al.
Publicado: (2020)

Decreased expression of farnesoid X receptor may indicate poor prognosis in patients with colorectal cancer
por: Zhang, Danying, et al.
Publicado: (2020)

Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
por: Fan, Chao, et al.
Publicado: (2015)

CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
por: Allouch, Awatef, et al.
Publicado: (2022)

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression
por: Liu, Wei, et al.
Publicado: (2020)

Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4
por: Xu, Qun, et al.
Publicado: (2022)

CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
por: Xu, Na, et al.
Publicado: (2015)

Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma
por: Li, Jia, et al.
Publicado: (2020)

Methylation of DIRAS1 promotes colorectal cancer progression and may serve as a marker for poor prognosis
por: Zheng, Ruipan, et al.
Publicado: (2017)

PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers
por: Siraj, Abdul K., et al.
Publicado: (2021)

Construction and validation of a novel algorithm based on oncosis-related lncRNAs comprising the immune landscape and prediction of colorectal cancer prognosis
por: Xiang, Haoyi, et al.
Publicado: (2022)

Upregulation of nectin-4 is associated with ITGB1 and vasculogenic mimicry and may serve as a predictor of poor prognosis in colorectal cancer
por: Zhang, Jinxiu, et al.
Publicado: (2019)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis
por: Bui, Nam Q., et al.
Publicado: (2019)

Co‐occurrence of CDKN2A/B and IFN‐I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma
por: Peng, Yuan, et al.
Publicado: (2022)

High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions
por: Fu, Lin, et al.
Publicado: (2017)

GLI3 Promotes Invasion and Predicts Poor Prognosis in Colorectal Cancer
por: Shen, Mingyang, et al.
Publicado: (2021)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Association of tricellulin expression with poor colorectal cancer prognosis and metastasis
por: Zhang, Jin-Xiu, et al.
Publicado: (2020)

The Cell Cycle-Associated Protein CDKN2A May Promotes Colorectal Cancer Cell Metastasis by Inducing Epithelial-Mesenchymal Transition
por: Shi, Wei-Kun, et al.
Publicado: (2022)

An immunogenic cell death-associated classification predictions are important for breast invasive carcinoma prognosis and immunotherapy
por: Liao, Xinghe, et al.
Publicado: (2022)

Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
por: Zong, Yuan, et al.
Publicado: (2023)

Comment on ‘Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?’
por: Liu, Yuying, et al.
Publicado: (2018)

Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma
por: Zhou, Qin, et al.
Publicado: (2022)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children
por: Ruan, Yang, et al.
Publicado: (2023)

High Spy1 expression predicts poor prognosis in colorectal cancer
por: Jin, Qin, et al.
Publicado: (2018)

Abnormal posterior semicircular canal function may predict poor prognosis in patients with severe and profound ISSNHL
por: Yang, Yang, et al.
Publicado: (2023)

Reduced RANBP9 expression is associated with poor prognosis in colorectal cancer patients
por: Wu, Guangbin, et al.
Publicado: (2019)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients
por: Yuan, Chong, et al.
Publicado: (2021)

Upregulation of SNTB1 correlates with poor prognosis and promotes cell growth by negative regulating PKN2 in colorectal cancer
por: Liu, Liya, et al.
Publicado: (2021)

Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1
por: Cassol, Clarissa, et al.
Publicado: (2019)

Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2022)

Intestinal obstruction: predictor of poor prognosis in colorectal carcinoma?
por: Mohd Suan, Mohd Azri, et al.
Publicado: (2015)

Podocalyxin is a marker of poor prognosis in colorectal cancer
por: Kaprio, Tuomas, et al.
Publicado: (2014)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ovog3vgdj86tbhjmbbdhtcc4f